專題討論9:COVID-19專題

S9-4
COVID-19最新治療
盛望徽教授
臺大醫院內科部

  Medical therapeutics to treat coronavirus disease 2019 (COVID-19) is evolving rapidly. The consensus of clinical management of COVID-19 consists of : (1) supportive care, such as oxygen support, mechanical ventilation if necessary; (2) antimicrobial agents for secondary bacterial infection; and (3) nutritional and fluid support. Mostly (80%) patients with COVID-19 are mild and recovery gradually. However, for high risk population and patients with progressive viral illness, such as oxygen demand and appearance of pulmonary infiltrates, anti-viral agents (such as remdesivir) and immune modulating agents for the treatment of COVID-19 should be considered according to the clinical situation. Understanding of COVID-19 pathogenesis, the disease is primarily driven by replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the early course and later by an exaggerated immune/inflammatory response (cytokine storm) to SARS-CoV-2 that leads to organ damage. Early effective treatment of therapy could avert progression to more serious illness, especially for patients at high risk of disease progression and severe illness, with the additional benefit of reducing the burden on healthcare systems. Clinical trials of novel therapeutics, such as monoclonal antibodies, assessed the potential effectiveness for early treatment are ongoing.